In its push to backstop sales of blockbuster Soliris, Alexion has touted its better-than-expected success at switching patients to follow-up drug Ultomiris. But if switching to the newer med is going ...
In the quest to match its predecessor Soliris, Alexion's Ultomiris just notched a win in the autoimmune disorder myasthenia gravis. Alexion is trumpeting data showing Ultomiris met its primary ...
Smarting from a patent defeat for cash cow Soliris in Europe, Alexion has dulled the pain with a phase 3 readout that sets up new filings for follow-up Ultomiris. The top-line data comes from a study ...
EXTON, PA, March 18, 2025 (GLOBE NEWSWIRE) -- Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and debilitating blood disorder that affects approximately 8,000 to 10,000 people in North America and ...
(Reuters) - The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc's treatment for a second rare blood disorder, the company said. The treatment, Ultomiris, has already ...
BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced plans to initiate a global Phase 3 study to investigate ULTOMIRIS® (ravulizumab-cwvz) in a subset of adults with ...
The safety profile of ULTOMIRIS was similar to that of SOLIRIS. Recently presented additional data showed that ULTOMIRIS provided immediate and complete C5 inhibition that was sustained for eight ...
BOSTON -- (EUREKALERT!) -- Alexion Pharmaceuticals, Inc. today announced the first conference presentation of the topline Phase 3 data for ULTOMIRIS ® (ravulizumab), the first and only long-acting C5 ...
Novartis has its eye on the market held by a pair of AstraZeneca's rare disease gems. The latest data showing that the Swiss drugmakers' iptacopan increases hemoglobin levels in a disease called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback